[KO Validated] Anti-IMPDH2 Monoclonal Antibody for WB, IF/ICC, ELISA - P12268

Core Product Specifications and Parameters

Biological Background: IMPDH2 Function and Localization

• Catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in de novo guanine nucleotide synthesis, thereby regulating cell growth. Related references: PMID:7763314 PMID:7903306
• Exhibits single-stranded nucleic acid-binding activity and may participate in RNA and/or DNA metabolism. Related references: PMID:14766016
• Implicated in the development of malignancy and the growth progression of certain tumors; expression profiling shows IMPDH2 predominates over IMPDH1 in tumor tissues.
• Localizes predominantly to the cytoplasm but can also be found in the nucleus and cytosol.
• Contains two CBS domains, functions as an oxidoreductase, and requires NAD and metal ions as cofactors.
• Underwent post-translational modifications including acetylation, phosphorylation, and ubiquitination, consistent with regulated protein turnover and signaling.

Experimental Guidance and Technical Tips

• The immunogen covers amino acids 100–300 of human IMPDH2, a region conserved across human, mouse, and rat, supporting the observed cross-reactivity. Sequence alignment may help predict reactivity with other species.
• For Western blotting, the expected band is approximately 56 kDa; consider using a KO-validated lysate pair as a stringent control to confirm band specificity.
• For immunofluorescence, typical nuclear and cytoplasmic staining should be expected; suitable fixation and permeabilization methods should be optimized.
• The antibody has been applied in ELISA; direct binding to the immunogen region suggests good suitability for quantitative assays, but dilution factors must be determined experimentally.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio streamlines IVD raw-material procurement for diagnostic manufacturers, clinical laboratories, and research institutes. This IMPDH2 monoclonal antibody complements our portfolio for cancer and nucleotide metabolism research, and we offer validated antibody pairs, optimized monoclonal/polyclonal reagents, bulk ancillary reagents, and rare-target sourcing to support your development from concept to clinic.